IRON DISC MEDICINE INC

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:

  • TD Cowen 45th Annual Health Care Conference (Boston, MA): Corporate presentation on Wednesday, March 5th at 9:10 a.m. ET.

  • Leerink Global Healthcare Conference (Miami, FL): Fireside chat on Monday, March 10th at 2:20 p.m. ET.
  • Barclays 27th Annual Global Healthcare Conference (Miami, FL): Fireside chat on Thursday, March 13th at 9:30 a.m. ET.

Disc management will be participating in investor meetings during each of the above conferences, as well as the Jefferies Biotech on the Beach Summit in Miami, FL. The Jefferies meetings take place on Tuesday, March 11th.

Live webcasts of the corporate presentation and fireside chats will be available through the investor relations section of the Company's website at and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi

Deerfield Group

Investor Relations Contact

Christina Tartaglia

Precision AQ



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to...

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned NDA submission for b...

 PRESS RELEASE

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Disc Medicine Appoints Nadim Ahmed to its Board of Directors WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. “I am excited to welcome Nadim to Disc’s Board of Directors at such a pivotal moment for the compan...

 PRESS RELEASE

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio...

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass.,...

 PRESS RELEASE

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5th at 10:30 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9...

 PRESS RELEASE

Disc Medicine Announces Multiple Presentations Across Portfolio at the...

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medici...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch